Vifor Fresenius Medical Care Renal Pharma AG
global pharmaceutical company
🤖
AI Overview
With $400K in lobbying spend across 12 quarterly filings, Vifor Fresenius Medical Care Renal Pharma AG is an active lobbying client. Their lobbying covers 2 issue areas. Active from 2023 to 2025.
$400K
Total Spend
3
Years Active
1
Firms Hired
6
Lobbyists Deployed
2
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2023 | $120K |
| 2024 | $180K |
| 2025 | $100K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Medicare/Medicaid, Health Issues
- •General education about end stage renal disease (ESRD) and kidney disease policies, including Medicare beneficiary access to pharmaceuticals.
- •General education about end stage renal disease (ESRD) and kidney disease policies.
- •General education about end stage renal disease (ESRD) and kidney disease policies, including Medicare beneficiary access to pharmaceuticals. H.R.5074, Kidney PATIENT Act of 2023.
Related Analysis
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Similar Clients
America's Health Insurance Plans INC (Ahip)
$96.4M total spend
U S Chamber Institute for Legal Reform
$58.7M total spend
Health Care Service Corporation, a Mutual Legal Reserve Company (Hcsc)
$52.8M total spend
GSK (FKA Glaxosmithkline INC.)
$39.9M total spend
National Association of Children's Hospitals (N.a.c.h.)
$38.0M total spend
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.